Studies which patient factors predict weight loss after endoscopic sleeve gastroplasty
Studies adults with obesity who had endoscopic sleeve gastroplasty, checking blood, stool and saliva samples.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty
- Status
- Recruiting
- People taking part
- 205 people, planned
- Started
- 9 Sept 2025
- Expected to end
- 2 Feb 2031
- Type of study
- Observational
- Treatments tested
- Bloed-, ontlasting- en speekselmonsters
- Record updated
- 21 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who have not lost weight with usual methods and are having endoscopic sleeve gastroplasty (a weight-loss procedure done through the mouth).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- BMI between 30 and 35 kg/m² with at least one obesity-related complication (diabetes, dyslipidemia, sleep apnea syndrome, non-alcoholic steatohepatitis, joint pain). Or BMI greater than 35 kg/m² and bariatric surgery has been refused.
- Earlier treatment
- Must have failed to lose weight and improve with conventional techniques. Cannot have taken antibiotics in the 3 months before joining. Cannot have had bariatric surgery before.
Main reasons for not taking part
- Antibiotics taken in the 3 months before joining
- Risk of gastric cancer needing regular endoscopic checks (extensive intestinal atrophy and/or metaplasia on biopsy)
- History of inflammatory disease of the stomach or gut, liver or kidney failure, or portal hypertension
- Peptic ulcer disease, including progressive peptic ulcer disease
- Previous bariatric surgery
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patient of legal age (Age ≥ 18 years)
- Patient capable of understanding the study and signing a consent
- BMI between 30 and 35 kg/m² with the presence of at least one one obesity-related complication (diabetes, dyslipidemia, sleep apnea syndrome, non-alcoholic steatohepatitis, joint pain joint pain)
- Patients with a BMI greater than 35 kg/m² who have been bariatric surgery has been refused
- Patient who has failed to lose weight and improve with conventional techniques
- Patient affiliated to a social security scheme
Who cannot take part
- Patient having taken antibiotics 3 months prior to inclusion
- Patient at risk of gastric cancer requiring regular endoscopic surveillance: extensive intestinal atrophy and/or metaplasia on biopsy
- Patient with a history of gastrointestinal inflammatory disease of gastric localization, hepatic or renal insufficiency, portal hypertension
- Patient with evidence of peptic ulcer disease and/or progressive peptic ulcer disease
- Patient with a history of bariatric surgery
- Patient under legal protection
- Patient with pathology affecting general health health and/or life expectancy
- Patient on AME
Where in France
- Hôpital Antoine BéclèreParis, FranceContact: Cosmin VOICAN, DoctorTaking people
About the trial
What the trial wants to find out
Endoscopic sleeve gastroplasty and bypass are currently available for weight loss in obese patients who have failed nutritional management. Despite very low risks, these techniques remain invasive. What's more, the French National Authority for Health recommends this procedure for patients with a BMI above 35 kg/m² with associated co-morbidities, or above 40 kg/m². This excludes grade I obese patients (30 < BMI < 35) who have no effective means of losing weight. The hospital's hepato-gastroenterology and nutrition department has therefore implemented endoscopic sleeve gastroplasty to address this problem. As with other surgical techniques, there is heterogeneity heterogeneity in weight loss. The investigators therefore aim to identify factors predictive of the efficacy of this procedure in order to improve patient management of patients.
Treatments tested
- Bloed-, ontlasting- en speekselmonsters
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty & Study the Evolution of Clinical, Biological and Intestinal Intestinal Microbiota After Surgery
- Plain-language title
- Studies which patient factors predict weight loss after endoscopic sleeve gastroplastyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 January 2026